Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354474 | 0.80 | ALDH1A1 (0.48) | TSHRALDH1A1KDM4EHTTMAPT | |
| SCHEMBL20511467 | 0.73 | TSHR (0.48) | TSHRALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL20540334 | 0.73 | TSHR (0.48) | TSHRALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL6155679 | 0.70 | ALDH1A1 (0.42) | TSHRALDH1A1KDM4EHTTMAPT | |
| SCHEMBL14441609 | 0.68 | ALDH1A1 (0.44) | TSHRALDH1A1KDM4EHTTMAPT | |
| SCHEMBL22897261 | 0.68 | ALDH1A1 (0.38) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL12994228 | 0.65 | ALDH1A1 (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL15415873 | 0.64 | — | — | |
| SCHEMBL11545787 | 0.64 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL2387688 | 0.64 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115626-A1 | BIFUNCTIONAL LINKER COMPRISING METAALLYLSILANE AND METHOD FOR PREPARING SAME | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2025-04-10 | — | — | US | disclosed |
| WO-2023128282-A1 | BIFUNCTIONAL LINKER COMPRISING METAALLYLSILANE AND METHOD FOR PREPARING SAME | 한양대학교 에리카산학협력단 | 2023-07-06 | — | — | WO | disclosed |
| US-9533957-B2 | Tetrazines and method of synthezising the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150099277-A1 | NOVEL TETRAZINES AND METHOD OF SYNTHEZISING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-09 | — | — | US | disclosed |
| US-20150099277-A1 | NOVEL TETRAZINES AND METHOD OF SYNTHEZISING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099277-A1 | NOVEL TETRAZINES AND METHOD OF SYNTHEZISING THE SAME | NBAS, NAA15, TALDO1 | TSHR 2649/4885PPM1B 3630/4885PTPN1 2619/4885 |
| US-20250115626-A1 | BIFUNCTIONAL LINKER COMPRISING METAALLYLSILANE AND METHOD FOR PREPARING SAME | MSN, MTCL3, TLN1 | TSHR 2699/4885PPM1B 1928/4885PTPN1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.